Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/30/2026

1. META
2. MSFT
3. FTNT
4. QCOM
5. ARM
6. SBUX
7. CVNA
8. TENB
9. CMG
10. EQIX

Go back to Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
XENCOR (NASDAQ: XNCR) Delayed: 21.09 +1.56 (7.99%)
Previous Close $19.53    52 Week High $26.50 
Open $19.68    52 Week Low $9.89 
Day High $21.24    P/E N/A 
Day Low $19.66    EPS $-0.51 
Volume 610,166